Pretreatment CD34+/CD38 – Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation

Myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasm (MPN) are heterogeneous clonal hematopoietic disorders resulting in inefficient hematopoiesis and a variable progression risk to secondary acute myeloid leukemia (sAML) [1-3]. At diagnosis, the International Prognostic Scoring System (IPSS) [1] and the revised IPSS (IPSS-R) [2] are commonly used to estimate disease aggressiveness for subsequent therapeutic decision-making. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment option for MDS patients and is of particular interest in high-risk disease [4].

Source: Biology of Blood and Marrow Transplantation - March 27, 2019 Category: Hematology Authors: Madlen Jentzsch, Ulrike Geus, Juliane Grimm, Vladan Vucinic, Wolfram P önisch, Georg-Nikolaus Franke, Gerhard Behre, Dietger Niederwieser, Sebastian Schwind Source Type: research